CD274 and acute myeloid leukemia: It is thought that there are factors other than PD-1 and PD-L1 that may aggravate their immunosuppression, influence their effects on immunotherapy, and contribute to the poor prognosis of AML patients (Stahl et al., 2019; Chen et al., 2020).